Citations

Clear

613 citation(s) found for "Zi, Ying".

Allocating scarce resources in real-time to reduce heart failure readmissions: a prospective, controlled study
Amarasingham, Ruben, Patel, Parag C. , Toto, Kathleen H., Nelson, Lauren L., Swanson, Timothy S. , Moore, Billy J. , Xie, Bin , Zhang, Song , Alvarez, Kristin , Ma, Ying , Kollipara, Usha K., Drazner, Mark H. , Halm, Ethan A. , Alvarez, Kristin

Mayo Clinic

BMJ Quality & Safety | August 1, 2013 | Volume: 22 | Issue: 12 | Pages: 998-1005

10.1136/bmjqs-2013-001901 | PMID 23904506 Get It

Objective To test a multidisciplinary approach to reduce heart failure (HF) readmissions that tailors the intensity of care transition intervention to the risk of the patient using a suite of electronic medical record (EMR)-enabled programmes. Methods A prospective controlled before and after study of adult inpatients admitted with HF and two concurrent control conditions (acute myocardial infarction (AMI) and pneumonia (PNA)) was performed between 1 December 2008 and 1 December 2010 at a large urban public teaching hospital. An EMR-based software platform stratified all patients admitted with HF on a daily basis by their 30-day readmission risk using a published electronic predictive model. Patients at highest risk received an intensive set of evidence-based interventions designed to reduce readmission using existing resources. The main outcome measure was readmission for any cause and to any hospital within 30 days of discharge. Results There were 834 HF admissions in the pre-intervention period and 913 in the post-intervention period. The unadjusted readmission rate declined from 26.2% in the pre-intervention period to 21.2% in the post-intervention period (p=0.01), a decline that persisted in adjusted analyses (adjusted OR (AOR)=0.73; 95% CI 0.58 to 0.93, p=0.01). In contrast, there was no significant change in the unadjusted and adjusted readmission rates for PNA and AMI over the same period. There were 45 fewer readmissions with 913 patients enrolled and 228 patients receiving intervention, resulting in a number needed to treat (NNT) ratio of 20. Conclusions An EMR-enabled strategy that targeted scarce care transition resources to high-risk HF patients significantly reduced the risk-adjusted odds of readmission.
Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial α5 Integrin
Cao, Ying , Hoeppner, Luke H. , Bach, Steven , Guangqi, E, Wang, Enfeng , Wu, Jianmin , Cowley, Mark J. , Chang, David K. , Waddell, Nicola , Grimmond, Sean M. , Biankin, Andrew V. , Daly, Roger J. , Zhang, Xiao Hui , E, Guangqi, Guo, Yan , Mukhopadhyay, Debabrata , Waddell, Nicola , Chang, David , Grimmond, Sean M , Biankin, Andrew V

Mayo Clinic

Cancer Research | May 21, 2013 | Volume: 73 | Issue: 14 | Pages: 4579-4590

10.1158/0008-5472.can-13-0529 | PMID 23689123 Get It

Abstract Metastasis, the leading cause of cancer death, requires tumor cell intravasation, migration through the bloodstream, arrest within capillaries, and extravasation to invade distant tissues. Few mechanistic details have been reported thus far regarding the extravasation process or re-entry of circulating tumor cells at metastatic sites. Here, we show that neuropilin-2 (NRP-2), a multifunctional nonkinase receptor for semaphorins, vascular endothelial growth factor (VEGF), and other growth factors, expressed on cancer cells interacts with α5 integrin on endothelial cells to mediate vascular extravasation and metastasis in zebrafish and murine xenograft models of clear cell renal cell carcinoma (RCC) and pancreatic adenocarcinoma. In tissue from patients with RCC, NRP-2 expression is positively correlated with tumor grade and is highest in metastatic tumors. In a prospectively acquired cohort of patients with pancreatic cancer, high NRP-2 expression cosegregated with poor prognosis. Through biochemical approaches as well as Atomic Force Microscopy (AFM), we describe a unique mechanism through which NRP-2 expressed on cancer cells interacts with α5 integrin on endothelial cells to mediate vascular adhesion and extravasation. Taken together, our studies reveal a clinically significant role of NRP-2 in cancer cell extravasation and promotion of metastasis. Cancer Res; 73(14); 4579–90. ©2013 AACR.
School Examinations Enhance Airway Inflammation to Antigen Challenge
Liu, Lin Ying, Swenson, Cheri A., Kelly, Elizabeth A. , Kita, Hirohito , Coe, Christopher L. , Busse, William W. , Kita, H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 165 | Issue: 8 | Pages: 1062-1067

10.1164/ajrccm.165.8.2109065 | PMID 11956045 Get It

Abstract Psychological stress can lead to asthma exacerbations in some patients. It is our hypothesis that the stress effect can occur through an enhancement of allergic inflammatory response. To investigate this possibility, airway antigen challenge was evaluated in 20 college students with mild asthma during both a low-stress phase (midsemester or two weeks postfinal examination) and a stress phase (final examination week). Subjects completed questionnaires to assess psychological state and underwent inhaled antigen challenge. Sputum samples were collected before challenge, and six and 24 hours and seven days postchallenge. Leukocytes were counted and eosinophil-derived neurotoxin (EDN) was measured in sputum supernates. Sputum cells were cultured and stimulated ex vivo with phytohemagglutinin (10 μ g/ml), and culture supernates were assayed for interleukin-5 (IL-5) and interferon- γ by enzyme-linked immunosorbent assay. Sputum eosinophils and EDN levels significantly increased at six and 24 hours postchallenge and were enhanced during the stress phase (p < 0.01). IL-5 generation by sputum cells was also increased at 24 hours during stress and correlated with airway eosinophils (rs = 0.65, p < 0.05). Students' anxiety and depression scores were significantly higher during the examination period. Our findings suggest that stress associated with final examinations can act as a cofactor to increase eosinophilic airway inflammation to antigen challenge and thus may enhance asthma severity.
Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression
Stallings‐Mann, Melody , Waldmann, Jens, Miller, Erin , Gauthier, Mona L., Visscher, Daniel W., Downey, Gregory P. , Radisky, Evette S. , Fields, Alan P. , Zhang, Ying , Radisky, Derek C. , Radisky, Evette S

Mayo Clinic

Science Translational Medicine | July 11, 2012 | Volume: 4 | Issue: 142 | Pages: No page available

10.1126/scitranslmed.3004062 | PMID 22786680 Get It

Rac1b mediates the matrix metalloproteinase–induced epithelial-mesenchymal transition in lung adenocarcinoma and is a potential therapeutic target in early-stage lung cancer.
Abstract 4975: Next generation sequencing reveals a connection between KRAS mutation and the NFkB pathway in lung adenocarcinoma samples
Asmann, Yan W. , Nair, Asha, Baker, Tiffany R., Carr, Jennifer M., Chai, High-Seng, Hossain, Asif, Passow, Jeanette E. Eckel, Kocher, Jean‐Pierre , Perez, Edith A. , Fields, Alan P. , Thompson, Aubrey, Kalari, Krishna R. , Rossell, David , Sun, Zhifu , Li, Ying , Middha, Sumit , Bot, Brian M.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 4975-4975

10.1158/1538-7445.am2011-4975 Get It

Abstract Motivation: KRAS is commonly mutated in a variety of cancers including lung cancer. The KRAS gene is frequently mutated at codons 12 and 13 in lung adenocarcinomas in patients with a history of smoking. Tumors harboring an activating KRAS mutation are aggressive and are often resistant to available therapies. In the present study, we set out to identify pathways that are specifically altered in lung cancer patients whose tumors harbor a KRAS mutation using next generation sequencing technology. Methods: We performed 50nt paired-end RNA-sequencing in 15 lung adenocarcinoma samples (8 and 7 samples with and without KRAS mutation). Reads were aligned to genome and exon junctions using Illumina's alignment tool ELAND_RNA. CASAVA and Genome Studio data analysis software were used to obtain read counts for genes, exons and exon junctions. We applied a variety of computational methods (Casper R package, Bowtie, TopHat) and softwares (Partek, R statistical software, JMP, Ingenuity Pathway Anlaysis, DAVID) to carry out our analyses. Results: Differential gene expression and splicing analysis were performed between the two groups. We identified 115 genes that were differentially expressed and 112 genes that consist of splicing variants with at least 2 fold changes and p-value < 0.01. We randomly selected 6/15 samples and performed real-time qRT-PCR for 6 differentially expressed genes. Significant correlations were observed ranging from 0.44 to 0.83, when qRT-PCR results were compared with RNA-sequencing expression data. Pathway analysis with 115 differentially expressed genes and 112 splicing variants revealed that the most significant pathway is composed entirely of NFκB focus genes, suggesting that there is a direct connection between oncogenic KRAS and activation of the NFκB signaling pathway. Conclusions: NFκB has been implicated in KRas-mediated formation of early stage lung adenomas in the LSL-Kas mouse model. Our data indicate that this connection also occurs in human lung cancer and establish NFκB activation as a key manifestation of KRAS mutation in human lung cancer. Hence drugs targeting NFκB and NFκB related genes may potentially be helpful for the treatment of patients with oncogenic KRAS mutations. (Supported in part by grants from the 26.2 with Donna Foundation and the Florida Department of Health Bankhead/Coley program.) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4975. doi:10.1158/1538-7445.AM2011-4975
Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment
Yaqoob, Usman , Cao, Sheng , Shergill, Uday, Jagavelu, Kumaravelu , Geng, Zhimin , Yin, Meng , Assuncao, Thiago M. de , Cao, Ying , Szabolcs, Anna, Thorgeirsson, Snorri S., Yang, Ju , Roberts, Lewis R. , Shah, Vijay H. , Yaqoob, Usman , Schwartz, Martin A. , Ehman, Richard L. , Mukhopadhyay, Debabrata , Roberts, Lewis R , Yin, Meng

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 72 | Issue: 16 | Pages: 4047-4059

10.1158/0008-5472.can-11-3907 | PMID 22738912 Get It

Abstract The tumor microenvironment, including stromal myofibroblasts and associated matrix proteins, regulates cancer cell invasion and proliferation. Here, we report that neuropilin-1 (NRP-1) orchestrates communications between myofibroblasts and soluble fibronectin that promote α5β1 integrin–dependent fibronectin fibril assembly, matrix stiffness, and tumor growth. Tumor growth and fibronectin fibril assembly were reduced by genetic depletion or antibody neutralization of NRP-1 from stromal myofibroblasts in vivo. Mechanistically, the increase in fibronectin fibril assembly required glycosylation of serine 612 of the extracellular domain of NRP-1, an intact intracellular NRP-1 SEA domain, and intracellular associations between NRP-1, the scaffold protein GIPC, and the nonreceptor tyrosine kinase c-Abl that augmented α5β1 fibronectin fibril assembly activity. Analysis of human cancer specimens established an association between tumoral NRP-1 levels and clinical outcome. Our findings indicate that NRP-1 activates the tumor microenvironment, thereby promoting tumor growth. These results not only identify new molecular mechanisms of fibronectin fibril assembly but also have important implications for therapeutic targeting of the myofibroblast in the tumor microenvironment. Cancer Res; 72(16); 4047–59. ©2012 AACR.
VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression
Cao, Ying , Guangqi, E, Wang, Enfeng , Pal, Krishnendu , Dutta, Shamit K., Bar‐Sagi, Dafna , Mukhopadhyay, Debabrata , Pal, Krishnendu

Mayo Clinic

Cancer Research | June 13, 2012 | Volume: 72 | Issue: 16 | Pages: 3912-3918

10.1158/0008-5472.can-11-4058 | PMID 22693250 Get It

Abstract VEGF/vascular permeability factor (VEGF/VPF or VEGF-A) is a pivotal driver of cancer angiogenesis that is a central therapeutic target in the treatment of malignancy. However, little work has been devoted to investigating functions of VEGF that are independent of its proangiogenic activity. Here, we report that VEGF produced by tumor cells acts in an autocrine manner to promote cell growth through interaction with the VEGF receptor neuropilin-1 (NRP-1). Reducing VEGF expression by tumor cells induced a differentiated phenotype in vitro and inhibited tumor forming capacity in vivo, independent of effects on angiogenesis. Autocrine activation of tumor cell growth was dependent on signaling through NRP-1, and Ras was determined to be a critical effector signaling molecule downstream of NRP-1. Our findings define a novel function for VEGF in dedifferentiation of tumor cells expanding its role in cancer beyond its known proangiogenic function. Cancer Res; 72(16); 3912–8. ©2012 AACR.
Memory and MRI-based hippocampal volumes in aging and AD
Petersen, Ronald C. , Jack, Clifford R. , Xu, Ying-Qi , Waring, Stephen C. , O’Brien, Peter C. , Ivnik, Robert J., Tangalos, E. G., Kokmen, E., Smith, Glenn E. , Boeve, Bradley F. , Waring, Stephen C. , Jack, Clifford R

Mayo Clinic

Neurology | May 13, 2012 | Volume: 54 | Issue: 3 | Pages: 581-581

10.1212/wnl.54.3.581 | PMID 10680786 Get It

Survival Analysis with Median Regression Models
Ying, Z. , Jung, Sin‐Ho , Wei, L. J.

Mayo Clinic

Journal of the American Statistical Association | April 24, 2012 | Volume: 90 | Issue: 429 | Pages: 178-184

10.1080/01621459.1995.10476500 Get It

Health Supervision in the Management of Children and Adolescents With IBD
Rufo, Paul A. , Denson, Lee A. , Szigethy, Eva , Sathya, Pushpa , Lu, Ying , Wahbeh, Ghassan, Sena, Laureen, Faubion, William A. , Sylvester, Francisco A.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | April 19, 2012 | Volume: 55 | Issue: 1 | Pages: 93-108

10.1097/mpg.0b013e31825959b8 | PMID 22516861 Get It

ABSTRACTUlcerative colitis (UC) and Crohn disease (CD), collectively referred to as inflammatory bowel disease (IBD), are chronic inflammatory disorders that can affect the gastrointestinal tract of children and adults. Like other autoimmune processes, the cause(s) of these disorders remain unknown but likely involves some interplay between genetic vulnerability and environmental factors. Children, in particular with UC or CD, can present to their primary care providers with similar symptoms, including abdominal pain, diarrhea, weight loss, and bloody stool. Although UC and CD are more predominant in adults, epidemiologic studies have demonstrated that a significant percentage of these patients were diagnosed during childhood. The chronic nature of the inflammatory process observed in these children and the waxing and waning nature of their clinical symptoms can be especially disruptive to their physical, social, and academic development. As such, physicians caring for children must consider these diseases when evaluating patients with compatible symptoms. Recent research efforts have made available a variety of more specific and effective pharmacologic agents and improved endoscopic and radiologic assessment tools to assist clinicians in the diagnosis and interval assessment of their patients with IBD; however, as the level of complexity of these interventions has increased, so too has the need for practitioners to become familiar with a wider array of treatments and the risks and benefits of particular diagnostic testing. Nonetheless, in most cases, and especially when frequent visits to subspecialty referral centers are not geographically feasible, primary care providers can be active participants in the management of their pediatric patients with IBD. The goal of this article is to educate and assist pediatricians and adult gastroenterology physicians caring for children with IBD, and in doing so, help to develop more collaborative care plans between primary care and subspecialty providers.